In the article by Zoccali et al (Zoccali C, Curatola G, Panuccio V, Tripepi R, Pizzini P, Versace M, Bolignano D, Cutrupi S, Politi R, Tripepi G, Ghiadoni L, Thadhani R, Mallamaci F. Paricalcitol and Endothelial Function in Chronic Kidney Disease Trial. Hypertension. 2014;64:1005–1011. doi:10.1161/HYPERTENSIONAHA.114.03748), which published online ahead of print on August 4, 2014, and appeared in the November 2014 issue of the journal, some corrections were needed. These changes do not alter the conclusion of the study.
1. On page 1007, Table 1, the Active and Place Group values of 25-OH vitamin D (in nmol/L) were 82.4±39.9 and 94.8±39.9, respectively. These have been changed to read, 33±16 and 38±16, respectively.
2. On page 1008, Table 2, the Paricalcitol and Placebo values of 25-OH vitamin D (in nmol/L) were 12.7 (2.0–23.5) and 5.0 (−10.0 to 20.2), respectively. These have been changed to read, 5.1 (0.8–9.4) and 2.0 (−4.0 to 8.1), respectively. The Difference (Paricalcitol vs Placebo) of 25-OH vitamin D (in nmol/L) was 7.7 (−10.7 to 25.9). This has been changed to read, 3.0 (−10.4 to 4.3).
The authors apologize for these errors.
These corrections have been made to the online version of the article, which is available at http://hyper.ahajournals.org/content/64/5/1005.full.
- © 2015 American Heart Association, Inc.